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ABBREVIATIONS 
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ABSTRACT 
 
Since national differences exist in genes, environment, diet and life habits and also in the use of 
postmenopausal hormone therapy (HT), the associations between different hormone therapies and 
the risk for breast cancer were studied among Finnish postmenopausal women.   
All Finnish women over 50 years of age who used HT were identified from the national medical 
reimbursement register, established in 1994,  and followed up for breast cancer incidence (n= 8,382 
cases) until 2005 with the aid of the Finnish Cancer Registry. The risk for breast cancer in HT users 
was compared to that in the general female population of the same age.  
Among women using oral or transdermal estradiol alone (ET) (n = 110,984) during the study period 
1994-2002 the standardized incidence ratio (SIR) for breast cancer in users for < 5 years was 0.93 
(95% confidence interval (CI) 0.80–1.04), and in users for  ≥ 5 years 1.44 (1.29–1.59). This therapy 
was associated with similar rises in ductal and lobular types of breast cancer. Both localized stage 
(1.45; 1.26–1.66) and cancers spread to regional nodes (1.35; 1.09–1.65) were associated with the 
use of systemic ET. Oral estriol or vaginal estrogens were not accompanied with a risk for breast 
cancer. 
The use of estrogen-progestagen therapy (EPT) in the study period 1994-2005 (n= 221,551) was 
accompanied with an increased incidence of breast cancer (1.31;1.20-1.42) among women using 
oral or transdermal EPT for 3-5 years, and the incidence increased along with the increasing 
duration of exposure (≥10 years, 2.07;1.84-2.30). Continuous EPT entailed a significantly higher 
(2.44; 2.17-2.72) breast cancer incidence compared to sequential EPT (1.78; 1.64-1.90) after 5 
years of use. The use of norethisterone acetate (NETA) as a supplement to estradiol was 
accompanied with a higher incidence of breast cancer after 5 years of use (2.03; 1.88-2.18) than 
that of medroxyprogesterone acetate (MPA) (1.64; 1.49-1.79). The SIR for the lobular type of 
breast cancer was increased within 3 years of EPT exposure (1.35; 1.18-1.53), and the incidence of 
the lobular type of breast cancer (2.93; 2.33-3.64) was significantly higher than that of the ductal 
type (1.92; 1.67-2.18) after 10 years of exposure.  
To control for some confounding factors, two case control studies were performed. All Finnish 
women between the ages of 50-62 in 1995-2007 and diagnosed with a first invasive breast cancer 
(n= 9,956) were identified from the Finnish Cancer Registry, and 3 controls of similar age 
(n=29,868) without breast cancer were retrieved from the Finnish national population registry. 
Subjects were linked to the medical reimbursement register for defining the HT use.  
The use of ET was not associated with an increased risk for breast cancer (1.00; 0.92-1.08). Neither 
was progestagen-only therapy used less than 3 years.  However, the use of tibolone was associated 
with an elevated risk for breast cancer (1.39; 1.07-1.81). The case-control study confirmed the 
results of EPT regarding sequential vs. continuous use of progestagen, including progestagen 
released continuously by an intrauterine device; the increased risk was seen already within 3 years 
of use (1.65;1.32-2.07). The dose of NETA was not a determinant as regards the breast cancer risk. 
Both systemic ET, and EPT are associated with an elevation in the risk for breast cancer. These 
risks resemble to a large extent those seen in several other countries. The use of an intrauterine 
system alone or as a complement to systemic estradiol is also associated with a breast cancer risk. 
These data emphasize the need for detailed information to women who are considering starting the 
use of HT. 
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INTRODUCTION 
 
Breast cancer is the most common malignancy among women in Western countries, and its 
incidence has increased in recent decades (Parkin et al 2001). In Finland, more than 4000 invasive 
breast cancers were diagnosed in 2007, which comprises one third of all female cancers 
(www.cancerregistry.fi). There are many explanations for the increase in the breast cancer 
incidence, such as organized mammographic screening programs (Moller et al 2005), increased 
life-expectancy and changes in established risk factors such as advanced age at first pregnancy, low 
parity and overweight (Hakulinen et al 1989). 
The majority of the risk factors are associated with either endogenous levels or the use of 
exogenous estrogens  (Yager and Davidson 2006); for instance, breast cancer occurs 150 times 
more often among women than men (Clemons and Goss 2001). Furthermore, more than 100 years 
ago, it was demonstrated that bilateral oophorectomy resulted in a remission of breast cancer in 
premenopausal women. Early menarche, late menopause, low parity and postmenopausal obesity 
are characterized with a prolonged exposure to endogenous estrogens and an increased breast 
cancer risk. Yet, not all risk factors are linked to estrogens, and e.g. genetic mutations or radiation 
(Ronckers et al 2005, Oldenburg et al 2007) may also lead to breast cancer.  
Because endogenous hyperestrogenism appears to predispose to breast cancer risk, it is no wonder 
that exogenous use of estrogens, alone or in combination with progestagen, is associated with an 
increased risk for breast cancer, as demonstrated in a pooled analysis of 51 epidemiological studies 
(Collaborative Group on Hormonal Factors in Breast Cancer 1997). Since then, numerous studies 
have analyzed the associations between the use of postmenopausal hormone therapy (HT) and 
breast cancer in different countries (Bakken et al 2004, Collins et al 2005, Fournier et al 2008, 
Flesch-Janys et al 2008). 
The use of HT, mammography screening programs, genes and lifestyles vary from one country to 
another (McPherson et al 2000, Clemons and Goss 2001, Key et al 2003, Oldenburg et al 2007). 
Therefore, it is possible that the HT use may have a nation-specific effect on the risk for breast 
cancer. The present studies aimed to clarify the risk for breast cancer among Finnish 
postmenopausal women using different HT regimens. 
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REVIEW OF THE LITERATURE 
 
Menopause 
Natural menopause is defined as a spontaneus cessation of natural menstruation for 12 consecutive 
months at 45-55 years (mean 50-52) (McKinlay et al 1992). A woman enters menopause through a 
perimenopause period of 4-5 years, when ovarian function declines gradually. The final cause for 
ovarian suppression may be a genetically controlled apoptosis (e.g. Vaskivuo and Tapanainen 
2003). At menopause, a drastic decline in circulating estrogens occurs, and this may lead to various 
symptoms and consequences (Stearns et al 2002). 
 
Immediate symptoms 
The symptoms which may occur before and/or within the first months of menopause are defined as 
immediate symptoms. They include vasomotor symptoms, such as hot flushes and night sweats, 
which are the most characteristic for menopause. Vasomotor symptoms are present in 70-80% of 
postmenopausal women (Stearns et al 2002). The reason for hot flushes is unknown, but the basis 
appears to be the hypoestrogenism-induced alteration in the hypothalamic thermo-regulatory centre 
(Sturdee 2008). Vasomotor symptoms almost always break the sleeping pattern and can be 
accompanied with dizziness and anxiety (Kopernik and Shoham 2004). A woman with hot flushes 
can also often be depressive. Immediate symptoms are the leading cause to initiate  HT use in 
clinical practice.  
 
Long term consequences 
Advancing age per se is certainly associated with a number of health risks. However, there are some 
specific conditions which start to appear in the postmenopause. 
 
Genital atrophy 
After the onset of menopause, the vaginal epithelium becomes atrophic, and the pH rises. Atrophy 
itself, or in association with inflammatory changes, can cause vaginal dryness, itching, discomfort 
and dyspareunia (Castelo-Branco et al 2005). Similar changes can occur in the urethral and/or 
bladder epithelium, which may predispose to urinary incontinence, dysuria and infections (Cardozo 
et al 1998). All these conditions become more common in postmenopausal women not using any 
estrogen therapy.  
 
Osteoporosis 
Both bone-forming osteoblasts and bone-resorpting osteoclasts have alfa and beta estrogen 
receptors (Bord et al 2001), indicating that bone is a target for estrogen. Bone mass, bone mineral 
density (BMD) and bone strength are highest around 25-35 years of age and remain stable until the 
menopause, when bone loss begins (Kleerekoper and Gold 2008). This is a result of 
hypoestrogenism, which induces bone resorption not compensated by adequate bone formation.  
Other hypoestrogenic conditions, such as premature ovarian failure, ovariectomy and anorexia also 
predispose to osteoporosis (American College of Obstetricians and Gynecologists Women's Health 
Care 2004). Bone loss can be 1-2% annually after menopause, being highest during the first 5-7 
years (Kanis and Melton 1994). Osteoporosis is defined by The World Health Organization criteria 
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as a BMD that is at least a 2.5 standard deviation below the average value for young, healthy 
women (T-score < -2.5). In Finland, it is estimated that approximately 400 000 people have 
osteoporosis and 30,000-40,000 osteoporotic fractures are diagnosed annually (The Finnish Current 
Care Guidelines, Finnish Medical Society Duodecim, www.kaypahoito.fi). According to a 
population based study in Eastern Finland, up to 7% of women aged 47-56 years are osteoporotic 
and every third woman of the same age osteopenic (T-score between -1- -2.5). (Tuppurainen M 
1995). It can be generalized that 40% of women over 50 years will experience a bone fracture 
during the rest of her lifetime, although a majority of fractures occur in women over 75 years 
(Kopernik and Sholam 2004). The high risk for osteoporosis after menopause is one important 
cause in clinical practice to initiate HT to preserve the bone.  
 
Cardiovascular diseases 
Before menopause, a woman’s risk to have a cardiovascular disease is considerably smaller as  
compared to men (Kopernik  and Sholam 2004), but this risk increases rather soon after menopause; 
the prevalence of cardiovascular diseases being equal among men and women by the age of 70 
(Lobo 2007). Furthermore, epidemiological studies have shown that premature menopause, either 
natural or artificial, increases the risk of cardiovascular disease, compared to menstruating women 
of the same age (Atsma et al 2006, Lokkegaard et al 2006). The causes of these phenomena are 
unknown, but the decline in estrogen levels after menopause is the most common explanation 
(Barret-Connor 1997). After menopause with declining estrogen levels, high-density lipoprotein 
cholesterol levels gradually decrease, and this decrease is greatest during the first year after 
menopause. With advancing age, triglycerides, systolic and diastolic pressure, weight and the levels 
of low-density lipoprotein cholesterol increases, together with increasing insulin resistance 
(Turgeon 2006, Collins et al 2007); these factors are important in developing cardiovascular 
diseases. There are several mechanisms by which estrogen may protect against the risk for 
cardiovascular diseases. Estrogen alters serum lipid concentrations by increasing high-density 
lipoprotein and decreasing low-density lipoprotein cholesterol levels.  It increases the production of 
vasoactive molecules, such as nitric oxide and prostacyclin, which are important factors in 
vasodilatation. Furthermore, estrogen increases insulin sensitivity, all of which in turn reduce the 
risk of vascular disorders (Lobo 2008).  
 
Cognition and dementia 
The brain is one of the target organs of estrogen. Estrogen enhances synaptic plasticity, neurite 
growth, hippocampal neurogenesis, and long-term potentiation, which is a process involved in the  
formation of episodic memories (Henderson 2008). During the menopause, many women report a  
worsening of the memory. This might be a secondary phenomenon to hot flushes and broken sleep, 
because there is no evidence that estrogen deficiency among postmenopausal women is a direct 
cause of cognitive decline (Alhola et al 2006, Herlitz et al 2007, Henderson 2008, Lethaby et al  
2008).  
Dementia can be caused by multiple factors, of which Alzheimer’s disease is the most common. 
Alzheimer’s disease is more common among postmenopausal women than in men of the same age 
(Burns and Iliffe 2009). This may hint at a role of hypoestrogenism as a cause of Alzheimer’s 
disease, but no such conclusive evidence exists so far. 
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Hormone therapy 
Estrogen-replacement therapy has been used for more than 60 years (Warren 2004, Stefanick 2005). 
In the US, conjugated equine estrogens (CEE), which are obtained exclusively from pregnant 
mares’ urine, have been used for substitution, while in Europe the predominant estrogen has been 
17beta-estradiol. The most common progestagen in the US is medroxyprogesterone acetate (MPA), 
but in Europe a large variety of different progestagens are available. In Scandinavia and the UK,  
norethisterone acetate (NETA) and levonorgestrel (LNG) are preferred, while MPA is used to a 
lesser extent. In Central and Southern Europe, micronized progesterone and dydrogesterone are 
predominant (Campagnoli et al 2005). Moreover, there are some alternatives to the traditional HT 
such as tibolone, testosterone, phytoestrogens and selective estrogen-receptor modulators (SERM).  
 
Estrogen-only therapy 
Estrogen-only therapy (ET) comprises systemic and vaginal use of estrogens, although in medical 
writing the term of ET is reserved to the systemic use of estrogen. According to the Finnish 
guidelines, only hysterectomized women can use systemic ET, because the long term ET is 
accompanied with a risk for endometrial cancer (Stefanick 2005). Estradiol is the only potent 
systemic estrogen available in Finland. There are many modalities to use systemic estradiol which 
is by far the most effective therapy for alleviating menopausal symptoms alone, or together with 
progestagen. Estradiol is also available vaginally (Table 1). Estradiol is oxidized reversibly to 
estrone and both estradiol and estrone are converted to estriol in the liver (Coelingh Bennink 2004). 
The significance of estriol as HT is limited, due to its poor estrogenic effect. However, vaginal use 
of estriol can alleviate vaginal atrophy.  
 
 
 
Table 1. Estrogens available for the use of 
postmenopausal women in Finland 
Administration Dose 
Oral   
  Estradiol 1.0mg, 2.0mg 
  Estriol 1.0mg, 2.0mg 
Transdermal 
  Patch 
  Gel 
 
25-100µg 
0.5mg, 1mg, 0.6mg/g, 1mg/g  
Vaginal  
  Estradiol 
    Tablet 
     Ring 
 
25µg 
7.5µg/24h 
  Estriol 
     Suppository 
     Creme 
 
0.5mg 
1.0mg/g, 0.1mg/g 
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Estrogen-progestagen therapy 
A progestagen component, as a complement to estrogen, is needed only in nonhysterectomized 
women. Progestagen protects the endometrium against hyperplasia and malignant transformation 
(Manson 2001), which ET use can cause.  Progestagen can be administered either sequentially, in 
addition to estrogen, for 10-14 days each month or continuously when both estrogen and 
progestagen are given every day. In a long cycle sequential regimen, progestagen is administered 
every three months for 14 days. Both oral and transdermal EPT preparations are available in fixed 
commercial preparations. In clinical practice, women often combine estrogen and progestagen 
individually. In Finland several regimens with different doses and administrations are available 
(Table 2). 
 
 
Table 2. Type and dose of progestagens in fixed commercial estrogen-progestagen therapy 
Sequential progestagen Dose (mg) Continuous progestagen Dose (mg) 
Oral  Oral  
   Norethisterone acetate 1    Norethisterone acetate 0.5, 0.7, 1 
   Medroxyprogesterone acetate 10, 20    Medroxyprogesterone acetate 2.5, 5 
   Levonorgestrel 0.25    Dydrogesterone 5 
   Dydrogesterone 10, 20    Drospirenone 2 
   Trimegestone 0.5   
Transdermal  Transdermal  
   Norethisterone acetate 0.17, 0.25    Norethisterone acetate 0.17, 0.25 
   Levonorgestrel 0.01, 0.02   
Type and dose of progestagens in individually formed EPT 
Oral  Intrauterine administration  
   Dydrogesterone 10-20    Levonorgestrel 0.02 
   Progesterone 100-300   
   Norethisterone  2.5-5   
   Medroxyprogesterone acetate 5, 10   
   Megestrol acetate 10   
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Progestagens 
Progestagens can be divided to natural progesterone and synthetic progestagens. Progesterone is the 
most specific and binds exclusively to a progesterone receptor. Dydrogesterone is closest to 
progesterone. It is retroprogesterone, a stereoisomer of progesterone and binds almost exclusively to 
progestagen receptors, thus having only effects mediated by progesterone receptors (Shindler et al 
2003). Synthetic progestagens can be further divided to 17alfa-hydroxyprogesterone derivates 
(MPA, megestol acetate) and 19-norprogesterone derivates (trimegestone), 19-nortestosterone 
derivates (norethisterone/acetate, lynestrenol, levonorgestrel) and spironolactone derivates 
(drospirenone) (table 3). They show some variation in biological activities, which is also dependent 
on the tissue concentrations of a given progestagen.  
 
Table 3. Biological activities of progestagens used in hormone therapy 
 pro-
gestogenic 
anti-
gonado-
tropic 
anti-
estrogenic 
estrogenic androgenic anti-
androgenic 
gluco-
corticoid 
anti-
mineralo-
corticoid 
Progesterone + + + - - ± + + 
Dydrogesterone + - + - - ± - ± 
Progesterone 
derivates 
        
MPA1 + + + - ± - + - 
Megestrol 
acetate 
+ + + - ± + + - 
Trimegestone + + + - - ± - ± 
         
Testosterone 
derivates 
        
Norethisteronea
cetate + + + + + - - - 
Levonorgestrel + + + - + - - - 
Lynesterol + + + + + - - - 
Spironolactone 
derivates 
        
Drospirenone + + + - - + - + 
(Adapted from Schindler 2003) + effective; (+-) weakly effective; (-) not effective. 1Medroxyprogesterone 
acetate. Data are based mainly on animal experiments.  
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Tibolone 
Tibolone is a synthetic steroid, the pharmacological and clinical profile of which is different from 
those of estrogens and progestagens. Tibolone taken orally is metabolized in the liver and intestine 
into active metabolites, two of which binds estrogen receptors and one which binds to progesterone 
and androgen receptors. Thus, tibolone has estrogenic, progestagenic and androgenic properties 
(Kloosterboer 2001, Notelovitz et al 2007). Tibolone use does not cause withdrawal bleedings. 
 
Selective estrogen receptor modulators, phytoestrogens, testosterone 
The selective estrogen receptor modulator (SERM) was originally defined as a compound that binds 
with high affinity to the estrogen receptor (ER), without significant binding activity to any other 
nuclear receptor. Later, SERMs were defined as a class of synthetic compounds which bind to the 
ER and produce agonistic activity in some tissues while being an estrogen antagonist in others 
(Riggs et al 2003). However, each SERM may have a unique clinical response which is not 
applicable to another SERM (Shelly et al 2008). Antiestrogenic effects of SERMs have been 
successfully used as adjuvant therapy (tamoxifen, toremifene) in the prevention of the recurrence of 
ER positive breast cancer. Raloxifene, another widely used SERM, is effective for the prevention of 
osteoporosis. Ospemifene, being now in phase III clinical trials, is well tolerated, does not cause or 
worsen hot flushes, and has an estrogenic effect on vaginal epithelium (Rutanen et al 2003). 
Ospemifene is comparable to raloxifene as regards effects on bone turnover and therefore, it may 
also be a potential drug for the prevention and treatment of osteoporosis in postmenopausal women. 
Plant extracts that exhibit estrogenic activities, are called phytoestrogens (Murkies et al 1998). 
Phytoestrogens are classified into three main classes: isoflavones, lignans, and coumestans. They 
have estrogen-like structure, which enables them to bind ERs, although they are not steroids. In 
alleviating menopausal symptoms, phytoestrogens are not proven to be effective (see e.g. Nikander 
et al 2003).   
Postmenopause is often characterized with low sexual desire (Sarrel et al 1998, Leiblum et al 
2006). This does not respond well to ET and/or EPT, which has led to the use of testosterone in 
women with low libido, because female sexual desire is in part androgen dependent (Somboonporn 
et al 2005). The European Agency for the Evaluation of Medical Products recently approved a 
testosterone patch as a therapy for hypoactive sexual desire. 
 
Effects of hormone therapy 
Although hormones used as the components of HT mimic natural hormones, and certainly give 
some benefits, it is understandable that they are also associated with desired and undesired effects; 
no medical agent is completely safe, because a risk of side-effects always exists (Table 4). 
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Table 4. Benefits, controversial effects and risks of long-term hormone therapy (references, 
see the text) 
Benefits Controversial effects Risks 
Alleviation of vasomotor symptoms Dementia Venous tromboembolism 
(oral therapy) 
Strengthening of  urogenital epithelium Coronary artery disease Stroke 
Prevention of osteoporosis  Endometrial cancer (ET2, sequential EPT) 
Protection against colon cancer  Breast cancer 
Protection against endometrial cancer 
(continuous EPT1) 
  
1Estrogen-progestagen therapy, 2estrogen-only therapy. 
 
 
 Benefits 
Improvement of vasomotor symptoms and urogenital atrophy 
Estrogen most effectively alleviates vasomotor symptoms already within a few days use (Notelowitz 
et al 2000, MacLennan 2001, and Stearns et al 2002), and this relief is dependent on the estrogen 
dose (Notelowitz et al 2000, Ettinger 2005, 2007). Because mood and sleep disturbances are 
strongly associated with vasomotor symptoms, relieving these symptoms improves the quality of 
life (Table 4.) (Welton et al 2008).  Estrogen therapy is also effective against urogenital atrophy. 
Both vaginal and systemic estrogen therapies are effective in this regard (Cardozo et al 1998). 
 
Prevention of osteoporosis 
Estrogen reduces the activity of osteoclasts and increases their apoptosis, thus decreasing the 
postmenopausal bone loss (Manolagas 2000). A meta-analysis of 22 trials on hormone therapy and 
fractures demonstrated an overall 27% reduction in nonvertebral fractures (Torgerson and Bell-Syer 
2001). The risk for vertebral fractures was 34% lower, and the risk for nonvertebral fractures was 
13% lower among HT users compared to nonusers (Wells et al 2002). The Women’s Health 
Initiative (WHI) trial was the first randomized clinical trial which showed a significant reduction of 
hip (hazard ratio (HR) 0.61;0.41-0.91) and vertebral fractures (HR 0.62; 0.42-0.93), with estrogen 
use among women without risk factors for osteoporosis (Anderson et al 2004). Because the BMD is 
the best single predictor of fracture risk in postmenopausal women, it has been used to evaluate the 
efficacy of drugs used for the treatment of osteoporosis. The bone strengthening effect of HT is 
established both in the spine and hip after 2 years of treatment (Wells et al 2002).  
 
Protection against colon cancer 
Meta-analyses have shown a reduction of 33-34% in colon cancer in users of HT (Nanda et al 1999, 
Grodstein et al 1999). The mechanism behind the protective effect of HT is not fully understood, 
although several theories have been suggested (Newcomb et al 2008). The Women’s Health 
Initiative reported a reduction of colorectal cancers by 37% among EPT users after a mean of 5.2 
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years of use, although the colon cancer of EPT users was diagnosed at a more advanced stage than 
that in the placebo group (Rossouw et al 2002). The reduction of the risk for colon cancer was not 
seen among ET users in another arm of the same study (Anderson et al 2004), although 
contradicting data on ET exist (Newcomb et al 1995, Johnson et al 2009).  
 
Controversial effects 
 
Alzheimer’s disease and dementia 
Estrogen may have neurotrophic and neuroprotective properties (Inestrosa et al 1998, Turgeon et al 
2006). This is supported by observational studies showing a 39-50% decline in the risk for 
Alzheimer’s disease among women using HT (Turgeon et al 2006). However, the only large 
randomized controlled trial could not confirm this result; on the contrary, the use of HT increased 
this risk. In this study, HT users were 65-79 years at the initiation of HT (Shumaker et al 2003, 
2004), which is not a typical age to start the use of HT. It is suggested that there can be a critical 
period when HT is still protective against dementia (Henderson 2008). Moreover, dementia in the 
randomized trial was mostly due to vascular reasons and not due to Alzheimer’s disease (Shumaker 
et al 2004). 
 
Coronary artery disease 
Observational studies have shown a significantly decreased risk for myocardial infarction among 
current HT users (Barrett-Connor and Grady 1998, Grodstein et al 2000). Yet,  this effect was not 
seen in randomized controlled trials. In contrast, HT appeared to elevate the risk of myocardial 
infarction both in primary (Rossouw et al 2002, Anderson et al 2004) and secondary prevention 
trials (Grady et al 2002). Recent meta-analysis concluded that HT reduces the risk of cardiac events 
among younger postmenopausal women, while among older postmenopausal women the risk 
increases during the first year of use, but decreases after 2 years of use (Salpeter et al 2006). 
Estrogen therapy initiated in women at 50 to 59 years of age may reduce plaque formation in the 
coronary arteries and then be protective against the risk of myocardial infarction in younger 
postmenopausal women (Mikkola and Clarkson 2002, Mikkola and Ylikorkala 2005, Manson et al 
2007). In this regard, hot flushes may be an important determinant, because they are associated with 
beneficial changes in endothelial function (see e.g. Tuomikoski et al 2009). 
 
Risks  
 
Venous tromboembolism 
The impact of estrogen on fibrinolysis and coagulation is complex. Estrogen reduces the fibrinogen 
concentration in plasma, activates fibrinolysis and thus, it increases the risk of venous 
tromboembolism (Grodstein et al 1996, Braunstein et al 2002). The association between HT use 
and venous tromboembolism is well demonstrated (Sare et al 2008, Canonico et al 2008), and it 
increases the risk of tromboembolism 2-fold (Rossouw et al 2002, Anderson et al 2004, Sare et al 
2008, Canonino et al 2008); the risk of venous tromboembolism being highest during the first year 
of use (Miller et al 2002). There is some evidence that EPT would increase the risk more than ET 
alone (Sare et al 2008), and this effect may be progestagen-specific (Canonico et al 2007). Recent 
studies have demonstrated a lower risk for the transdermal administration of estrogen compared to 
an oral one, or no risk at all (Scarabin et al 2003, Canonico et al 2007).  
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Stroke 
The increased risk of stroke among ET (HR 1.39; 1.10-1.77, mean follow-up 6.8 years) (Anderson 
et al 2004) and EPT (1.41; 1.07-1.85, mean follow-up 5.2 years) (Rossouw et al 2002) users was 
one of the reasons which led to an early termination of the WHI randomized controlled trials. A 
previous large observational study (Nurses’ health study) had reported a slightly elevated risk for 
stroke (relative risk (RR) 1.35; 1.08-1.68) among ET/EPT users with the dose of ≥ 0.625 mg CEE. 
However, the lower dose was not associated with an increased risk for stroke (Grodstein et al 
2000). A meta-analysis of observational studies, including the Nurses’ health study, showed an 
increased stroke incidence among ever users of HT (Miller et al 2002), but the Heart and 
Estrogen/progestagen Replacement Study, a randomized controlled trial on the effect of EPT on 
coronary heart disease, reported no increase in strokes (Grady et al 2002). The recent analysis of the 
Nurses’ health study evaluated the risk for stroke among younger and older women using HT, but 
the risk appeared not to be related to the age at the initiation of HT (Grodstein et al 2008). 
 
Endometrial cancer 
A prolonged use of estrogen predisposes to the hyperplasia and malignant transformation of the  
endometrium (Smith et al 1975). A one year use of unopposed estrogen is accompanied with a 1.4- 
fold risk for endometrial cancer, and in 10 years of use the risk increases 9.5-fold. The risk of 
estrogen can be eliminated by adding progestagen to estrogen, either sequentially or continuously 
(Manson et al 2001). The continuous EPT regimen is associated with an even smaller risk of 
endometrial cancer than in women not using HT (Weiderpass et al 1999, Wells et al 2002). The risk 
reduction of endometrial cancer was also seen in a Finnish study after 3 years of use (standardized 
incidence ratio (SIR) 0.24; 95% CI 0.06-0.60). However, the use of a sequential EPT regimen for 5 
years was accompanied with a modest risk elevation (1.69; 1.43-1.96) (Jaakkola et al 2009, 
accepted for publication).  
 
Breast cancer 
Approximately every 10th woman in Finland will have breast cancer during her life-time, and 
almost every woman has at least one friend or relative affected by this disease. Therefore, it is no 
surprise that breast cancer is the leading cause for cancer fear, despite the considerably improved 
prognosis of this disease. 
  
Diagnostics and screening   
The diagnosis of breast lesions includes palpation, imaging the breast by mammography or 
ultrasound and histological or cytological examination by fine needle aspiration or thick needle 
biopsies (Hermansen et al 1987). The most common imaging method of breasts is the 
mammography. Population-based screenings were started in Finland in 1987. All women between 
50-62 years are invited to screenings (in some communities up to age of 69) every second year. The 
coverage of the screenings in Finland is 95-100% (Dean and Pamilo 1999, Sarkeala et al 2008), 
and 90% of the invited women take part in these screenings.  
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Incidence 
Breast cancer is the most common cancer among women comprising one fifth of all cancers 
worldwide (Bray et al 2004, Colditz et al 2006). The incidence has been increasing in recent 
decades (Figure 1) (Engholm et al 2009), and in 2007, 4160 new breast cancer cases were 
diagnosed in Finland, comprising 31% of all female cancer cases. Breast cancer is more common in 
large urban areas (Figure 2) and has been more common among women with higher socioeconomic 
status (www.cancerregistry.fi). 
 
 
 
Figure 1. Number of women diagnosed with breast cancer in ages 45-85+  during 1953-2007  
in Finland (Engholm et al 2009) 
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Figure 2. Incidence of breast cancer in Finland in 1997-2006 (www.cancerregistry.fi) 
 
 
 
 
 
 
 
 
 
Survival and mortality 
In recent decades, the mortality for  breast cancer has been decreasing (Hermon and Beral 1996, 
Boyle and Ferlay 2005). In Finland the mortality was 14.4 per 100,000 in 2007, and the relative 5-
year survival rate in 2003-2005 was 89% (www.cancerregistry.fi). It has been calculated that the 
screening reduces the breast cancer mortality by 22% (Sarkeala et al 2008). 
 
Risk factors 
Breast cancer is a multifactoral disease, which is affected by reproductive, hormonal and genetic 
factors. Lifestyle and environmental features are also involved. (Table 4).  
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Table 4. Some risk factors for breast cancer  
Factor Risk group1 Relative 
risk (RR) 
Sex Female  150 
Age ≥ 50   > 6.5 
Age at menarche  Menarche before age 12 1.5-3.0 
Age at menopause  Menopause after age 54 2.0 
Age at first birth First child after 30 1.9-3.5 
Parity Nulliparous 1.4 
Benign breast disease 
 
Proliferative lesion with atypia 
Proliferative lesion without atypia 
3.5-5 
1.5-2.0 
Family history of breast cancer Breast cancer in first degree relative > 2.0 
Height > 175 cm 1.5 
Weight Postmenopausal BMI2 > 35 2.0 
Alcohol use 2 drinks/day  1.2 
Exposure to ionising radiation Abnormal exposure in young females after age 10 3.0 
Modified from McPherson 2000, Clemons and Goss 2001, Singletary 2003. 1Relative risk 
compared with the low-risk population. 2 Body mass index. 
 
 
Gender 
Female gender is a strong risk factor for breast cancer. Women have a 150-fold higher breast cancer 
risk than men (Clemons and Goss 2001, Engholm et al 2009). This is evidently due to female sex 
hormones. Conditions which lead to high estrogen levels in men are also associated with male 
breast cancer (Weiss 2005).  
 
Advanced age 
Breast cancer incidence increases rapidly after age of 40, but after the age of 65 the incidence 
decreases (Figure 3). Mammographic screening program from 1987 in Finland has been 
accompanied with an increased incidence of breast cancer among women aged 50-59 as 
demonstrated in figure 3 (Engholm et al 2009).  
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Figure 3. Incidence of breast cancer in 1963 and 2007 in Finland, by age. The organised 
mammography screening of breast cancer was started in 1987 (Engholm et al 2009) 
 
 
Age at menarche and menopause 
Women experiencing menarche before 12 years have a 50% higher risk for breast compared to 
women having menarche when older than 14 years (Clemons and Goss 2001). Likewise, the 
delayed menopause is associated with a risk elevation of 3% for each delayed year (Cuzick 2003). 
Both early menarche and late menopause increase the length of lifetime exposure to endogenous 
female sex hormones which hints at the importance of these hormones in the development of breast 
cancer. 
 
Age at first birth and parity 
Full-term pregnancy has a protective effect against breast cancer risk. During pregnancy, both 
estrogen and progestagen cause proliferation and differentiation of the ductal and lobular-alveolar 
epithelium, which ultimately reduces the risk for malignant transformation of the breast tissue 
(Russo et al 1982). Human breast tissue also contains receptors for human chorionic gonadotropin 
and luteinizing hormones. Human chorionic gonadotropin and pregnancy may affect the expression 
of certain genes and growth factors which inhibit cell proliferation. Human chorionic gonadotropin 
may be the most important protective factor (Russo and Russo 2000). The earlier the first full-term 
pregnancy has occurred, the lower the risk (Ramon 1996 et al, Hinkula et al 2001). Women older 
than 30 at first delivery have a 2- 3.5 –fold higher risk for breast cancer, compared to women whose 
first delivery was before 21(Ramon et al 1996, Hinkula et al 2001). The risk of breast cancer 
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decreases by approximately 10% per birth (Ewertz et al 1990, Hinkula et al 2001). Even if the first 
birth is at age 30 or later, multiparity (5 deliveries) has a protective effect against breast cancer 
(Hinkula et al 2001).  
 
Benign breast disease 
Heterogenous groups of proliferative and non-proliferative breast lesions are defined as benign 
breast diseases. These include benign tumors, trauma, mastalgia, mastitis, and nipple discharge 
(Miltenburg and Speights 2008). Non-proliferative lesions are not associated with breast cancer 
risk, but proliferative lesions, either with (3.5-5-fold) or without atypia (1.5-2-fold), are associated 
with an increased  risk for breast cancer (Cuzick 2003). Proliferative diseases account for 25-30% of 
all benign breast diseases, of which 5-10% show proliferative lesions with cellular atypia. Both 
benign and malignant breast disease can present similar symptoms with a palpable mass or an 
abnormal screening mammogram with no clinical findings (Miltenburg and Speights 2008). 
 
Family history 
Approximately 30% of all breast cancer patients have relatives with breast cancer (Lichtenstein et al 
2000). If a first-degree relative has breast cancer, the risk for breast cancer is elevated 
approximately 2-fold (Collaborative Group on Hormonal Factors in Breast Cancer 2001, 
Oldenburg 2007). The risk increases with the number of relatives affected and is greater for women 
with relatives affected at young age (Olderburg et al 2007). The overall lifetime breast cancer risk 
for women without a family history of breast cancer is 7.8%. For those who have one first degree-
relative affected, the risk is 13.3%, and for those having two,  the risk is 21.1% (Collaborative 
Group on Hormonal Factors in Breast Cancer 2001).  
 
Breast cancer genes 
It has been approximated that 5-10% of all breast cancers are caused by mutations in well-identified 
breast cancer susceptibility genes. The two most important mutations are the high-risk breast cancer 
genes BRCA1 and BRCA2. However, these mutations only account  for a part of the genetic 
susceptibility of breast cancer (Oldenburg 2007). In a large meta-analysis, the  cumulative risk for 
breast cancer by age 70 among BRCA1 carriers was 65%, and among BRCA2 carriers the risk for 
breast cancer was 46% (Antoniou et al 2003). In a Finnish study, the risk for breast cancer among 
first-degree relatives of a BRCA1 carrier was 6-12 fold, and for a BRCA2 carrier 5-11-fold (Eerola 
et al 2001). 
 
Alcohol use 
Alcohol use is associated with an increased risk for breast cancer (Longnecker 1994, Smith-Warner 
et al 1998, Zhang et al 2007). This elevation may be 9-11% with a daily consumption of one 
alcoholic drink (10g/d) (Longnecker 1994, Smith-Warner 1998), and the risk increase is linear up to 
6 drinks. The mechanism of alcohol-induced elevation in breast cancer risk is unknown, but 
increased levels of estrogen and androgen appear important. Alcohol may also enhance the  
susceptibility of mammary cells to carcinogenesis and increase the metastatic potential of breast 
cancer cells (Singletary and Gapstur 2001). 
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Size of a woman  
Obesity is associated with a risk for breast cancer. However, obesity in childhood has not proven to 
have an effect on the risk of breast cancer later in life (Huang et al 1997), but weight gain after the 
age of 18 or after menopause is associated with increased risk of breast cancer among 
postmenopausal women (Eliassen et al 2006). On the contrary, a higher body mass index (BMI) at 
18 years is associated with a lower risk of breast cancer in premenopausal life and, in some studies 
in postmenopausal life as well (Huang et al 1997). A high BMI (>31 vs. < 21) is also associated 
with a 46% lower risk for breast cancer in premenopause (Friedenreich 2001). One explanation for 
the increased risk for breast cancer after menopause in obese women is the high amount of 
endogenous estrogens produced in adipose tissue. Furthermore, obesity increases the circulating 
concentrations of insulin, which may be associated with the risk for breast cancer (Friedenreich 
2001). Tall women appear to have a higher risk for breast cancer (Friedenreich 2001). Childhood 
energy intake, the cumulative exposure to growth hormone and insulin-like growth factor-I, or the 
number of ductal stem cells in the mammary gland have been proposed as potential biologic 
mechanisms associated with an increased breast cancer risk among tall women.  
 
Hormone therapy and breast cancer 
As evidenced before, conditions characterized with endogenous hyperestrogenism are associated 
with an elevated risk for breast cancer. Therefore, it is expected that the exogenous use of female 
sex steroids may increase the risk for breast cancer. A pooled analysis of 51 epidemiological studies 
defined the association between breast cancer and HT (Collaborative Group on Hormonal Factors 
in Breast Cancer 1997). This finding has been confirmed later by numerous studies (see reviews 
Collins et al 2005, Lee et al 2005). However, recent reports which have focused on more precise 
analyses on the association between different therapies and breast cancer have produced 
inconclusive data. So far, only one randomized controlled trial has had enough power to evaluate 
the breast cancer risk with different hormone therapies. This study failed to found any association 
with breast cancer and estrogen-only therapy (CEE 0.625 mg/d) in 6.8 years’ of use (HR 0.77, 95% 
CI 0.59-1.01) (Anderson et al 2004) but the EPT (CEE 0.625 mg/d and MPA 2.5 mg/d) was 
accompanied with an elevated risk for breast cancer   (1.24; 95% CI 1.01-1.54) (Rossouw et al 
2002). This result, together with the adverse effects of HT on cardiovascular events, has changed 
the policy of prescribing HT in the Western world. 
 
Estrogen-only therapy 
A meta-analysis of 45 studies on the use of ET revealed no association between ET and the risk of 
breast cancer (Bush et al 2001).  Later on, numerous observational studies have reported either an 
increased risk or no impact on the risk for breast cancer associated with the use of ET (table 5). The  
largest cohort study so far showed that the current use of ET was accompanied by an increased risk 
for breast cancer (RR 1.25, 95% CI 1.10–1.41) already in 1-4 years of use (Beral et al 2003). In 
contrast, ET in a placebo-controlled study (CEE) was associated with an almost statistically 
significant decrease in the risk for breast cancer (HR 0.77; CI 0.59–1.01) (Anderson et al  2004). In 
a Finnish study on ET use, the mean duration of 8.2 years, was not accompanied with an increased 
risk for breast cancer (Sourander et al 1998). However, the association between ET and breast 
cancer may be relative to the duration of the use (Table 5). 
 
 
 25
Table 5. Previous data on the use of estrogen-only therapy and the risk for breast cancer  
 
Study Design Type of 
estrogen 
Duration of use RR/HR/OR2 
Collaborative 
Group on 
Hormonal Factors 
in Breast Cancer 
1997 
Pooled analysis of 
51 studies 
(Median age at first 
use 48 years) 
52,705 cases 
 mostly CEE1 < 5 years 
≥ 5 years 
0.99  (0.065) 
1.35  (1.21-1.49) 
Sourander et al 
1998 
cohort 
7,944 
97 cases 
estradiol mean duration 8.2 
years 
1.00  (0.47-1.90) 
Magnusson et al 
1999 
 
case-control 
(50-74 years) 
3,345/3,454 
mostly 
estradiol 
≤ 2 years 
> 2 ≤ 5 years 
> 5 ≤ 10 years 
10+ years 
1.72  (1.13-2.62) 
1.49  (0.85-2.63) 
2.18  (1.07-4.45) 
2.70  (1.47-4.96) 
Colditz et al 2000 cohort 
(50-70 years) 
58,520 
1,761 cases 
CEE 10 years  1.23  (1.06-1.42) 
Shairer et al 2000 cohort (BMI ≤ 24.4) 
(58+ years) 
46,335 
mostly CEE < 8 years 
8 < 16 years 
≥ 10 years 
1.00  (0.80-1.30) 
1.50  (1.20-2.00) 
1.60  (1.20-2.20) 
Chen et al 2002 case-control 
(50-74 years) 
705/692 
CEE ≤ 3 years 
> 3 < 5 years 
≥ 5 years 
1.13  (0.64-2.01) 
1.45  (0.84-2.49) 
1.84  (1.04-3.27) 
Kirsh et al 2002 case-control 
(20-74 years) 
404/403 
not given 1-9 years 
≥ 10 years 
1.00  (0.44-2.24) 
1.74  (0.93-3.24) 
Newcomb et al 
2002 
case-control 
(50-79 years) 
5,298/5,951 
mostly CEE < 5 years 
≥ 5 years 
1.08  (0.92-1.27) 
1.36  (1.17-1.58) 
Porch et al 2002 cohort  
(≥ 45 years) 
17 835 
411 cases 
not given < 5 years 
≥ 5 years 
0.95  (0.64-1.40) 
0.87  (0.65-1.53) 
Weiss et al 2002 case-control 
(35-64 years) 
1,870/1,953 
not given 6 mo < 2 years 
2 < 5years 
5+ years 
0.83  (0.55-1.27) 
1.00  (0.67-1.50) 
0.97  (0.68-1.37) 
Li et al 2003a case-control 
(65-79 years) 
975/1,007  
not given 6 months < 5 years 
≥ 5 < 15 years 
≥ 15 < 25 years 
≥ 25 years 
0.80  (0.60-1.20) 
1.20  (0.80-1.70) 
1.30  (0.90-1.90) 
1.00  (0.70-1.40) 
Olsson et al 2003 cohort 
29,508 
556 cases 
estradiol 1-4 years 
> 4 years  
0.77  (0.38-1.57) 
0.58  (0.22-1.55) 
Beral et al 2003 cohort 
1,084,110 
(50-64 years) 
9364 cases 
CEE/estradiol 1-4 years 
5-9 years 
≥ 10 years 
1.25  (1.10-1.41) 
1.32  (1.20-1.45) 
1.37  (1.22-1.54) 
Anderson et al 
2004  
RCT3  
(50-79 years) 
10,739 (94 vs 124) 
CEE 6.8 years 0.77  (0.59-1.01) 
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Bakken et al 2004 cohort  
(45-64 years) 
67,336 
624 cases 
not given < 5 years 
≥ 5 years 
2.50  (1.40-4.50) 
1.00  (0.40-2.50) 
Stahlberg et al 
2004 
cohort  
(≥ 45 years) 
19,898 
244 cases  
estradiol Mean duration 7.2 
years 
1.96  (1.16-3.35) 
Fournier et al 2008 cohort  
(mean age at start of 
HT 52.4 years) 
80 337 
2,354 cases 
mostly 
estradiol 
Mean duration 7 
years 
1.29  (1.02-1.65) 
Flesch-Janys et al  
2008 
case-control  
(50-74 years) 
3,464/6,657 
not given < 5 years 
5-<10 years 
10-<15 years 
15+ years 
0.92  (0.80-1.07) 
1.13  (0.94-1.35) 
1.16  (0.95-1.43) 
1.09  (0.85-1.39) 
Opatrny et al 2008 case-control 
(50-75 years) 
6,347/31,516 
mostly CEE Mean duration 
2891 days 
1.22  (0.74-2.00) 
1Conjugated equine estrogens; 2RR=relative risk, HR=hazard ratio, OR=odds ratio; 3randomized placebo-
controlled trial 
 
 
Route of administration 
The impact of the route of administration of estrogen for health benefits and non-malignant risks 
has been much studied (see e.g. Cacciatore et al 2001, Strandberg et al 2003, Scarabin et al 2003, 
Canonico et al 2007). In contrast, the data on whether the estrogen effect on breast cancer is 
dependent on the route of administration are sparse. The English study found no difference between 
oral and transdermal administration as regards to the risk for breast cancer, but the analyses were 
based only on the regimen which was used at the time of interview (Beral et al 2003). Yet, previous 
data may imply that the different estrogenic milieu in users of oral and transdermal estrogen might 
similarly affect breast cells.  
 
Dose 
A longer exposure to estrogen appears to be limited to the higher risk for breast cancer, as discussed 
above. Therefore, it may be plausible that also the dose of estrogen is a determinant, although in a 
pooled analysis of 51 epidemiological studies no differences between various doses of CEE were 
determined (Collaborative Group on Hormonal Factors in Breast Cancer 1997). Furthermore, in a 
large cohort study of 58 520 nurses (Colditz et al 2000), no dose-dependence was found, whereas in 
another study, a trend toward higher relative risks with higher doses of CEE was seen (Porch et al 
2002). The study in the UK failed to show any dependence between the doses of estradiol and CEE 
and the risk for breast cancer (Beral et al 2003).  
 
Estrogen-progestagen therapy 
It is generally accepted that postmenopausal EPT is accompanied with a higher risk of breast cancer 
than estrogen alone (Table 6). This risk elevation is primarily attributed to the progestagen 
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component of EPT; the first data published on this association was already in the late 80s (Bergkvist 
et al 1989). Later, particularly that therapy with CEE for a mean 6.8 years was not associated with 
an increased risk of breast cancer (Anderson et al 2004, Collins et al 2005), but CEE given together 
with progestagen, was associated with an increased risk of breast cancer in 5.2 years (Rossouw et al 
2002), confirmed this association.   
 
Mode of administration and duration of use 
It can be concluded from the above that progestagen as a complement to estrogen appears to be an 
established risk factor. The mode of progestagen administration may also be a significant 
determinant. Abundant data have shown that sequential administration appears safer than  
continuous use (Magnusson et al 1999, Weiss et al 2002, Newcomb et al 2002, Jernström et al 
2003, Olsson et al 2003 Stahlberg et al 2004, Flesch-Janys et al 2008), although data are not 
uniform in this regard (Ross et al 2000, Beral et al 2003, Li et al 2003a, Opatrny et al 2008).  
Additionally, there is no clear-cut duration of exposure after which the risk for breast cancer 
increases significantly. In less than 5 years of use, a slightly increased risk associated with either 
sequential or continuous progestagen use is seen (Magnusson et al 1999, Ross et al 2000, Chen et al 
2002, Bakken et al 2004) (table 6).  
 
Type of progestagen 
Progestagens can act as a proliferative or as an antiproliferative agent in the breast, depending on 
the dose, type of progestagen, and duration of exposure. Progestagens can bind with various steroid 
receptors with different affinity and exert different effects on breast cell proliferation, to modify 
estrogen metabolizing enzymes, cell cycle, growth factors and oncogenes (Pasqualini et al 1998). 
Several in vitro studies have shown differences between progestagens towards normal breast cells 
and breast cancer cells (Seeger and Mueck 2008). Progestagens may also induce proliferation in 
breast tissue through paracrine mechanisms, i.e. in the circumstances which cannot be modelled in 
the culture cell lines (Lange 2008). Therefore, discordant opinions exist on the effects of various 
progestagens on breast cancer risk. 
Medroxyprogesterone acetate has been primarily used in US studies, and the increased breast cancer 
risk associated with MPA containing EPT was confirmed in the WHI trial (Rossouw et al 2002).  In 
Scandinavia, norethisterone acetate (NETA) and levonorgestrel (LNG) are the most common 
progestagens, and in Scandinavian studies, the risk for breast cancer has been reported to be slightly 
higher compared to the US studies (Lee et al 2005). This may imply that NETA and LNG could 
carry a higher risk than MPA. It has been speculated that MPA, being a 17alfa-hydroxyprogesterone 
derivate, affects breasts more physiologically than NETA, which is a derivate of 19-nortestosterone 
(Campagnoli et al 2005). However, a large cohort study from the UK reported no marked 
differences between MPA, NETA and levonorgestrel (Beral et al 2003). In France, where the most 
used progestagens are dydrogesterone and progesterone, no increased risk of breast cancer was seen 
among users of these progestagens combined with estrogen (Fournier et al 2008). It should also be 
noted that the preferred estrogen component in the USA is CEE, in contrast to Scandinavian 
countries where estradiol is a leading commercial estrogen. Therefore, it may not be justified to 
compare only different progestagens and the risk for breast cancer between various countries if the 
estrogen component of EPT is not the same. 
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Table 6. Previous data on estrogen-progestagen therapy (EPT) and risk for breast cancer  
 
Study Design Mode of regimen Duration of use RR/HR/OR1 
Magnusson et al 
1999 
case-control 
(50-74 years) 
3,345/3,454 
EPTsequential  
 
 
 
 
EPTcontinuous  
 
 
 
≤ 2 years 
> 2 ≤ 5 years 
> 5 ≤ 10 years 
10+ years 
 
≤ 2 years 
> 2 ≤ 5 years 
> 5 ≤ 10 years 
10+ years 
1.58  (1.01-2.46) 
1.34  (0.71-2.54) 
1.89  (0.88-4.09) 
2.45  (0.82-7.30) 
 
0.93  (0.63-1.36) 
1.26  (0.76-2.09) 
2.89  (1.66-5.00) 
5.36  (1.47-19.56) 
Ross et al 2000 case-control 
(55-72 years) 
1,897/1,637 
EPTsequential 
 
 
 
EPTcontinuous 
 
≤ 5 years 
> 5 ≤ 10 years 
10+ years 
 
 
≤ 5 years 
> 5 ≤ 10 years 
10+ years 
 
1.19 
1.58 
1.79  
per 5 y 1.38 (1.13-
1.68) 
 
0.88 
1.28 
1.23 
per 5 y 1.09 ns (0.88-
1.35) 
Chen et al 2002 case-control 
(50-74 years) 
705/692 
EPTsequential 
 
 
 
EPTcontinuous 
≤ 1 years 
> 1 < 3 years 
≥ 3 
 
≤ 6 months 
7-19 months  
≥ 20 months 
1.37  (0.85-2.20) 
1.00  (0.59-1.71) 
1.62  (1.03-2.55) 
 
0.85  (0.36-2.03) 
1.32  (0.60-2.89) 
1.85  (1.03-2.55) 
Newcomb et al 
2002 
case-control 
(50-79 years) 
5,298/5,951 
EPT 
 
 
EPTsequential 
EPTcontinuous 
<5 years 
≥ 5 years 
 
1.32  (1.02-1.70) 
1.50  (1.09-2.06) 
 
0.96  (0.70-1.31) 
1.54  (1.15-2.07) 
Olsson et al 2003 cohort 
29,508 
556 cases 
EPTsequential  
 
 
EPTcontinuous 
 
1-4 years 
> 4 years 
 
1-4 years 
> 4 years 
1.18  (0.62-2.23) 
1.44  (0.67-3.08) 
 
2.01  (1.14-3.55) 
3.13  (1.70-5.75) 
Weiss et al 2002 case-control 
(35-64 years) 
1,870/1,953 
EPTsequential  
 
 
 
EPTcontinuous 
 
 
< 2 years 
2-<5 years 
5+ years 
 
< 2 years 
2-<5 years 
5+ years 
0.72  (0.42-1.24) 
1.44  (0.79-2.61) 
1.18  (0.70-1.98) 
 
1.11  (0.71-1.75) 
1.38  (0.86-2.22) 
1.77  (1.04-3.01) 
Li et al 2003a case-control 
(65-79 years) 
975/1,007  
EPTsequential 
 
 
 
 
EPTcontinuous 
6 months < 5 years 
≥ 5 < 15 years 
≥ 15 years 
 
6 months < 5 years 
≥ 5 < 15 years 
≥ 15 years 
1.50  (0.80-2.80) 
1.70  (1.00-3.00) 
2.90  (1.30-6.60) 
 
1.30  (0.90-2.00) 
2.00  (1.30-3.00) 
1.80  (1.00-3.30) 
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Beral et al 2003 cohort 
(50-64 years) 
1,084,110 
9,364 cases 
EPTsequential  
 
EPTcontinuous  
 
< 5 years 
≥ 5 years 
< 5 years 
≥ 5 years 
1.77  (1.59-1.97) 
2.12  (1.95-2.30) 
1.57  (1.37-1.79) 
2.40  (2.15-2.67) 
Chlebowski et al 
2003 
RCT2 
(50-79 years) 
16,608 
199 vs 150 cases 
EPTcontinuous 5.2 years 1.24  (1.01-1.54) 
Bakken et al 2004 cohort  
(45-64 years) 
67,336 
624 cases 
EPTsequential  
 
 
EPTcontinuous 
 
< 5 years 
≥ 5 years 
 
< 5 years 
≥ 5 years 
1.70  (1.00-2.80) 
2.20  (1.30-3.80) 
 
2.60  (1.90-3.70) 
3.20  (2.20-4.60) 
Jernström et al 
2004 
cohort  
(50-64 years) 
6,586 
101 cases 
EPTcontinuous ≤ 2 years 
> 2 ≤ 4 years 
> 4 years 
3.00  (1.30-7.00) 
1.50  (0.45-5.30) 
3.20  (1.40-7.20) 
Stahlberg et al  
2004 
cohort  
(≥ 45 years) 
19,898 
244 cases 
EPTsequential  
 
 
 
EPTcontinuous 
 
 
< 5 years 
5-9 years 
10+ years 
 
< 5 years 
5-9 years 
10+ years 
1.58  (0.79-3.17) 
2.47  (1.23-4.95) 
2.18  (1.09-4.33) 
 
1.96  (0.72-5.36) 
4.96  (2.16-11.39) 
6.78  (3.41-13.48) 
Ewertz et al 2005 cohort 
(40-67 years) 
78,380  
1462 cases 
EPTsequential current use 1.52  (1.21-1.93) 
Opatrny et al 2008 case-control 
(50-75 years) 
6,347/31,516 
EPTsequential  
EPTcontinuous 
Mean duration 
2681 days 
1.33 (1.21-1.46) 
1.29 (1.07-1.56) 
 
Flesch-Janys et al 
2008 
case-control  
(50-74 years) 
3,464/6,657 
EPTsequential  
 
 
 
 
EPTcontinuous 
< 5 years 
5-<10 years 
10-<15 years 
15+ years 
 
< 5 years 
5-<10 years 
10-<15 years 
15+ years 
1.03  (0.87-1.22) 
1.30  (1.10-1.54) 
1.39  (1.13-1.69) 
1.37  (1.04-1.80) 
 
1.11  (0.96-1.28) 
1.88  (1.59-2.23) 
2.04  (1.66-2.50) 
1.91  (1.46-2.49) 
1 RR=relative risk, HR=hazard ratio, OR=odds ratio; 2 randomized placebo-controlled trial 
 
 
 
Route of administration 
Oral EPT has been in use much longer than transdermal EPT. Therefore, most data on the risk of 
breast cancer in HT users have been accumulated from its oral use. Progestagen for endometrial 
protection can be administered by intrauterine system and such a use of levonorgestrel was not 
associated with increased risk of breast cancer among women aged 35-54, but these women were 
not treated with estrogen (Backman et al 2005).  
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Tibolone  
Tibolone is a synthetic steroid which is metabolized to estrogenic, progestagenic and androgenic 
compounds (Vos et al 2002). Tibolone alleviates climacteric symptoms and protects against 
osteoporosis (Notelovitz 2007). The association between tibolone and breast cancer is controversial. 
In epidemiological studies, tibolone (2.5mg/d) is either accompanied with an increased risk for 
breast cancer (Beral et al 2003, Stahlberg et al 2004) or has no effect (Opatrny et al 2008). In 
contrast, a randomized trial on osteoporotic elderly women demonstrated that a smaller dose of 
tibolone (1.25mg/d) led to a significantly reduced risk for breast cancer (Cummings et al 2008). 
However, in a recent big placebo controlled trial in women with a history of breast cancer, the use 
of tibolone (2.5mg/d) was associated with a 48% increase in the risk of new cancer or recurrence 
within  4 years of use (Kenemans et al 2009). It has been hoped that the vascular effects of tibolone 
could be enhanced in combination with phytoestrogens, but the tibolone+soya combination proved 
to have rather minimal vascular benefits over the sole tibolone (see e.g. Jernman 2008); no such 
data exist as regards the effects of tibolone on breast. 
 
Selective estrogen receptor modulator, testosterone, phytoestrogens  
Tamoxifen is currently considered the gold standard for adjuvant therapy in the treatment of 
hormone sensitive breast cancer (Shelly et al 2008). Raloxifene also reduces the risk for new 
invasive breast cancer (Shelly et al 2008). Overall, SERMs act as opposites to estrogen or have a 
neutral effect in the breast. For the adjuvant treatment of hormone sensitive postmenopausal breast 
cancer, aromatase inhibitors appear to be more effective than tamoxifen, and they will replace the 
SERMs. 
The data on the association of breast cancer and testosterone are limited. In a recent study, the use 
of testosterone for more than 5 years was not associated with an increased risk for breast cancer 
(van Staa and Sprafka 2009). It has even been suggested that testosterone could counteract breast 
cell proliferation induced by EPT (Hofling et al 2007). 
Despite the weak estrogenic effects of phytoestrogens, epidemiological studies suggest that the 
incidence of breast cancer is lower in countries where the intake of phytoestrogens is high, implying 
that these compounds may reduce the breast cancer risk (Adlercreutz 2003). However, short-term 
intervention studies suggest a possible stimulatory effect on breast tissue, raising concerns of 
possible adverse effects in breast cancer patients. Presently, no clear evidence exists as regards the 
guidelines for the clinical use of phytoestrogens in healthy women or in women with a history of 
breast cancer (Rice and Whitehead 2008).  
 
Levonorgestrel releasing intrauterine system with estrogen 
The levonorgestrel releasing intrauterine system (LNG-IUS) was designed for contraception 
(Nilsson et al 1981). It can also be used for endometrial protection in postmenopausal estrogen 
users and it was introduced as part of the EPT in the early 90s (Andersson et al 1992). Due to the 
small release of LNG (20µg/d), LNG-IUS as a complement to estrogen has been assumed to be safe 
for breasts (Sitruk-Ware 2007). This hypothesis is supported by data on fertile age women in whom 
the risk for breast cancer was not increased with the use of LNG-IUS (Backman et al 2005). 
However, no data existed on the relation between LNG-IUS+estrogen and breast cancer among 
postmenopausal women at the time of planning of the present study. 
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Histology of breast cancer  
The most common histologic type of breast cancer is ductal (70-80% of all breast cancer types) 
followed by the lobular type of cancer (5-10% of all types) (www.cancerregistry.fi). Cancer can 
also be ductal-lobular, tubular, medullary and mucinous, and these classes only amount to a 
minority of all breast cancers (Reeves et al 2006). For an unknown reason, the rate of lobular cancer 
has increased more than that of ductal cancer in recent years (Verkooijen et al 2003, Li et al 2003b). 
Ductal cancer is more easily detected in a mammogram, but the prognosis for the lobular type of 
breast cancer is better than that for ductal cancer (Verkooijen et al 2003, Li et al 2000,2008). It is a 
general consensus that the use of HT favours the occurrence of lobular, ductal-lobular and tubular 
types of breast cancer (Collins et al 2005, Reeves et al 2006, Borgquist et al 2007, Li et al 2008, 
Fournier et al 2008). 
It has been hypothesized that EPT could act as a promoter of foci of lobular carcinoma that would 
remain small or perhaps clinically undetectable in the absence of EPT exposure (Li et al 2008). 
This theory is supported by the studies which reveal an increased risk for breast cancer in a rather 
short duration of exposure (Magnusson et al 1999, Beral et al 2003, Bakken et al 2004, Jernström 
et al 2004, Li et al 2008). It has been calculated that it can take approximately 7-10 years before a 
cancerous DNA change leads to  clinically diagnosed breast cancer (Speroff 2008). Therefore, the 
disappearance of the risk elevation for breast cancer within 5 years after the cessation of EPT use 
may also support the speculation that HT would not initiate a new cancer (Collaborative Group on 
Hormonal Factors in Breast Cancer 1997, Collins et al 2005). 
 
Other characteristics of breast cancer 
Many observational studies have reported that the breast cancers in HT users are smaller (Holli et al  
1998, Magnusson et al 1999, Delgado and Lopez 2001, Cheek et al 2002, Sacchini et al 2002,  
Daling et al 2003, Schuetz et al 2007) and of a lower histological grade (Holli et al 1998, 
Magnusson et al 1999, Delgado and Lopez 2001,  Sacchini et al 2002, Daling et al 2003, Borgquist 
et al 2007, Schuetz et al 2007), but data are not conclusive in this regard (Chlebowski et al 2003, 
Kerlikowski et al 2003, Stahlberg et al 2004). Furthermore, breast cancer among HT users is more 
often local (Manjer et al 2001, Delgado and Lopez 2001, Cheek et al 2002), although contradicting 
data also exist in this regard (Chlebowski et al 2003, Kerlikowske et al 2003). A randomized 
controlled trial found no difference in tumour receptor status among EPT users compared to 
nonusers (Chlebowski et al 2003), while various observational studies have found the association 
between ER+  tumours and EPT (Delgado and Lopez 2001, Daling et al 2002, Kerlikowske et al 
2003, Chen et al 2004, Hwang et al 2005, Fournier et al 2008). The association is less evident 
between ET and ER+ (Chen et al 2004) tumours.  
 
Women with a history of breast cancer 
The use of HT has been considered to be contraindicated among women diagnosed with breast 
cancer. However, the survival rate for breast cancer has been improved, and numbers of survivors 
with climacteric symptoms are willing to consider HT. A Finnish study reported no increased risk 
among breast cancer survivors using HT for short durations (mean 2.5 years) (Metsä-Heikkilä  
2001). Later a meta-analysis of 8 observational studies also revealed no increased risk of recurrence 
among HT users after treatment of breast cancer (Col et al 2005). However, a randomized study 
comparing HT for menopausal symptoms with management without HT among breast cancer 
survivors was discontinued early (median 4 years), due to the increased risk of new breast cancer 
following HT (HR 2.4; 1.3-4.2) (Holmberg et al 2008).  
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AIMS OF THE STUDY 
 
Due to the national differences in the pattern of HT use and background factors contributing to the 
risk for breast cancer, the impact of HT use for breast cancer should be studied in each country 
where HT is being used. The purpose of this study was to evaluate the impact of the common HT 
regimens used in Finland on the risk for breast cancer.  
The specific aims were to analyse the impact of doses, routes of administration of progestagens and 
estrogens, and various progestagens as regards the risk for breast cancer. Consequently, the  
following studies were performed: 
1. Estrogen-only therapy and the risk for breast cancer (cohort study) (I) 
2. Estrogen-progestagen therapy and the risk for breast cancer (cohort study) (II) 
3. Hormone therapy including intrauterine system and tibolone and the risk for breast cancer 
(case-control study) (III) 
4. Dose and route of norethisterone acetate (as a part of HT) as a determinant of breast cancer 
risk (case-control study) (IV) 
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SUBJECTS AND METHODS 
 
All studies were register-based (Table 7), and the use of different registers in each study are 
described below. 
Postmenopausal hormone therapy is currently reimbursed for  42% of the price.  
The Finnish Population Information System contains basic information about Finnish citizens and 
foreign residents in Finland. Personal data recorded in the system includes name, personal identity 
code, address, citizenship and native language,  family relations and date of birth and death (if 
applicable). 
 
Table 7. Registers used in the present study 
 
Register Complete data 
available 
Used in following studies 
during the given period  
Medical reimbursement 
register (The social 
insurance institution of 
Finland) 
all reimbursable 
hormone therapy 
regimens since 1994 
Study I        
Study II       
Study III      
Study IV      
1994-2001 
1994-2005 
1994-2007 
1994-2007 
Finnish Cancer Registry 1953 Study I        
Study II       
Study III      
Study IV      
1994-2001 
1994-2005 
1995-2007 
1995-2007 
Finnish Population 
Register Centre 
1969 Study III      
Study IV      
1995-2007 
1995-2007 
 
Study population in cohort studies 
The study cohort of ET users consisted of all women over 50 years (n=110,984) who had purchased 
for at least 6 months any type of estrogen-only regimen in 1994–2001, the first purchase being at 
the age of 50 or later (table 8). These women were identified from the medical reimbursement 
register of the Social Insurance Institution of Finland. The women who had bought regimens for 
less than 6 months use were excluded, because this group could include women who had only 
bought estrogens, but not used them. Only 387 women had bought CEE, and thus, these women 
were not included in the analysis. Our final cohort consisted of women using estradiol and estriol-
based regimens. 
The cohort of EPT users consisted of all women over 50 (n=221,551) who had bought EPT 
regimens in 1994-2005 for at least 6 months with the first purchase being at the age of 50 or later 
(Table 8).  
The follow-up for breast cancer among HT users was done through the Finnish Cancer Registry 
using personal identifiers as the key. 
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Study population in case control studies 
All 9,956 women in Finland diagnosed with breast cancer at 50-62 years of age during 1995-2007 
were identified through the Finnish Cancer Registry (Table 8).  For each case subject, three control 
women of the same age (+/- one month) and alive at the time of diagnosis of the respective case 
were randomly selected from the Finnish national population registry. Cases and controls were 
linked to the medical reimbursement registry providing the data on the use of HT. The subgroup 
analysis of NETA containing HT use was done among HT users of cases and controls. All women 
who were included in case control studies, turned 50 years at some point during the study period, 
and the exposure to HT was calculated from 50 years on. 
 
Table 8. Study populations 
 
 Cohort Cases/ controls Age of the subjects Follow-up period 
Study I 110,984  ≥ 50 1994-2002 
Study II 221,551  ≥ 50 1994-2005 
Study III  9,956/ 29,868 50-62 1995-2007 
Study IV  885/ 1,430 50-62 1995-2007 
 
 
Statistical methods 
The standardized incidence ratios (SIRs) were calculated by dividing the number of observed cases 
by the numbers expected. Ninety-five per cent confidence intervals (95% CIs) for the SIRs were 
based on the assumption that the number of observed cases represents a Poisson distribution. The 
expected numbers of breast cancer cases were calculated by multiplying the number of 
person-years in each 5-year age group by the corresponding breast cancer incidence among all 
Finnish women during the same period of observation (ww.cancerregistry.fi).        
The follow-up for all HT users started in 1994 and ended for ET users at the end of 2002 or at death 
and for EPT users at  the end of 2005 or at death. 
Odds ratios (OR) and 95% CIs were used as measures of relative risk in the case control studies. 
These were computed from logistic regression models estimated by a conditional maximum 
likelihood method. The age of a woman, the age at first birth, parity, and health care district served 
as confounders and were adjusted in the final models. The two-tailed test was used for comparison 
of proportions. 
 
Ethics and permissions 
The ethics committee of the Department of Obstetrics and Gynecology, Department of 
Othorhinolaryngology, Department of Neurology and Neurosurgery, HUCS, The National Institute 
for Health and Welfare (former STAKES) and the Social Insurance Institution of Finland have 
given permissions for this study.  
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RESULTS 
 
Detailed results are given in the original publications, and therefore only the main results are 
presented here. 
Estradiol-only therapy and the risk for breast cancer (study I) 
Altogether, 2171 cases with breast cancer were reported to the Finnish Cancer Registry during the 
follow-up. The use of systemic estradiol was associated with an increased incidence of breast 
cancer after 5 years of exposure (Table 9). Oral estriol or vaginal use of estrogen were not 
accompanied with any increased incidence of breast cancer (Table 9). 
The elevated incidence of breast cancer associated with ET use increased with the increasing daily 
dose of oral estradiol, and the incidence was significantly elevated with the highest mean daily dose 
of estradiol (≥ 1.9 mg/day) in users of ≥ 5 years.  However, the trend by dose was not statistically 
significant (p-trend = 0.27).  
The use of patches of all doses for ≥ 5 years was accompanied by an elevated incidence for breast 
cancer. Most of the gel users had used > 0.9 mg/day (90%, n=867) ≥ 5 years, and the SIR was 1.52 
(0.73–2.78). Transdermal use of ET for ≥ 5 years at any dose was associated with an increased 
incidence of breast cancer, which was comparable to that of oral ET. 
The incidence of lobular type of breast cancer among ET users ≥ 5 years (1.58; 1.22-2.01) did not 
differ from  that of ductal cancer (1.36; 1.19-1.53). The use of ET for ≥ 5 years was associated with 
an increased incidence of both localized cancer and cancer spread to regional nodes. The SIR for 
carcinoma in situ was 2.43 (1.66–3.42) among ET users for ≥ 5 years. 
Table 9. Standardized  incidence ratios (SIR) of breast cancers among women (N) using oral 
or transdermal estradiol, oral estriol and vaginal estrogens by duration of use1 
Duration N Obs Exp SIR 95 % CI 
Estradiol      
≥ 6 months < 5 years2 28 380 340 363 0.93 0.80-1.04 
≥ 6 months < 5 years3 29 445 1166 895 1.30 1.23-1.38 
≥ 5 years 26 904 345 239 1.44 1.29-1.59 
Estriol      
≥ 6 months < 5 years2 2857 34 35 0.98 0.68-1.37 
≥ 6 months < 5 years3 3717 88 82 1.07 0.86-1.32 
≥ 5 years 1367 16 11 1.41 0.80-2.28 
Vaginal estrogens      
≥ 6months < 5 years2 7 303 43 64 0.67 0.48-0.90 
≥ 6 months < 5 years3 10 879 138 130 1.06 0.89-1.25 
≥ 5 years 132 1 0.71 1.41 0.04-7.86 
1Use in ages over 50 years during 1994-2001, observed (Obs) and expected (Exp) number of breast 
cases up to 31 December 2002, and standardized incidence ratios (SIR) with their 95 % confidence 
intervals (CI). 
2Only users from 1995-2001(with completely known exposure history) were included. 
3Users from 1994 (with possible preregister use) were included. 
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Estrogen-progestagen therapy and the risk for breast cancer (study II) 
Altogether 6211 EPT users became diagnosed with breast cancer during the study period. The use 
of EPT for at least 3 years was associated with an increased incidence of all breast cancer types 
combined (1.31; 1.20-1.42) (Table 10). The SIR increased with increasing exposure to EPT, being 
2.07 (1.84-2.30) after 10 years of use (Table 10).  
The sequential and continuous use of progestagen as a complement to estradiol were accompanied 
with elevated risks for breast cancer from 3 years of exposure onwards. The use of progestagen 
continuously was associated with a higher risk elevation than the sequential use of progestagen 
after 5 years. Oral and transdermal EPT regimens showed comparable risk elevations. The risk was 
also elevated in EPT users with inaccurate exposure data (Table 11). 
 
Table 10. Standardized incidence ratios (SIR) of invasive breast cancer in women with the use 
of estradiol-progestagen therapy1  
Exposure N Obs Exp SIR 95% CI 
≥ 6 months < 3 years 50 033 1024 976 1.05 0.97-1.11 
≥ 3 years < 5 years 30 583 547 418 1.31 1.20-1.42 
≥ 5 years < 10 years 32 466 472 273 1.72 1.58-1.89 
≥ 10 years 23 131 299 146 2.07 1.84-2.30 
1Use in women over 50 years during 1994-2005, observed (Obs) and expected (Exp) number of breast 
cancer cases up to the end of December 2005, and standardized incidence ratios (SIR) with their 95% 
confidence intervals (CI) at the end of the follow-up. 
 
 
Table 11. Standardized incidence ratios (SIR) of invasive breast cancer (N) among women using 
estrogen+progestagen therapy in 1994-2005 according to the mode  of regimen, and duration of 
the use1 
 Sequential Continuous 
Exposure N SIR (95% CI) N SIR (95% CI) 
≥ 6 months < 3 years2 781 1.04 (0.97-1.11) 253 1.24 (1.12-1.37) 
≥ 3 years < 5 years2 385 1.09 (0.96-1.23) 105 1.42 (1.16-1.71) 
≥ 5 years3 738 1.78 (1.64-1.90) 294 2.48 (2.09-2.91) 
≥ 10 years4 27 2.27 (1.50-3.30) 21 5.12 (0.62-18.48) 
1Use in ages over 50 during 1994-2005, observed (Obs) and expected (Exp) number of breast cancer 
cases up to 31 December 2005, and standardized incidence ratios (SIR) with their 95% confidence 
intervals (CI) at the end of the follow-up. 
2Classification according to first use. 
3Used the same mode of administration for 5 years. 
4Used the same mode of administration for 10 years. 
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The use of EPT containing NETA was accompanied with a significantly higher risk for breast 
cancer than the use of MPA after 5 years of use (Table 12). Exposure to other progestagens, 
including dydrogestrone, showed no statistically significant increase in the risk for breast cancer in 
less than 5 years of use (1.22; 0.83-1.72).  The mixed use of progestagens for 5 years or more 
(NETA and MPA switchers included) was accompanied with an elevated risk for breast cancer.  
 
 
Table 12. Standardized incidence ratios (SIR) of invasive breast cancer among women 
(N) using estrogen+progestagen therapy in 1994-2005 grouped according to the 
progestagen, and duration of use1   
 N Obs Exp SIR 95% CI 
Progestin type 
and duration      
> 6 mo < 3 years2      
NETA 22368 439 424 1.04 0.94-1.14 
MPA 13438 336 324 1.04 0.93-1.15 
≥ 3 years < 5 years2      
NETA 12211 266 169 1.34 1.17-1.51 
MPA 8648 166 130 1.27 1.09-1.48 
≥ 5years3       
NETA 24093 670 330 2.03 1.88-2.18 
MPA 19299 454 277 1.64 1.49-1.79 
Other4   5804 159 77 2.07 1.76-2.04 
Mixed5 39727 860 498 1.73 1.61-1.84 
≥ 10 years3      
NETA 4081 67 21 3.15 2.44-4.00 
MPA 2049 16 8 1.90 1.07-3.07 
Other4 289 6 2 2.79 1.02-6.07 
Mixed5 6492 70 30 2.33 1.82-2.94 
1Use in ages over 50, observed (Obs) and expected (Exp) number of breast cancer cases up to 
the end of December 2005, and SIRs with their 95 % confidence intervals (CI) at the end of 
the follow-up. 
2Classified according to the first EPT. 
3Classified according to the progestagen used first and at 5 and at 10 years (pre-register use 
possible.  
4Includes progestagens other than NETA, MPA and dydrogesterone. 
5Switching use of progestagen.  
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The users of NETA formed large enough groups for a comparison between the impacts of 
sequential or continuous use of progestagen on the risk for breast cancer. Within the use of at least 
5 years, the sequential use of NETA (1.72; 1.52-1.93) was accompanied with a significantly lower 
incidence of breast cancer than the continuous use (2.56; 2.25-2.88). The SIR of breast cancer 
increased up to 1.90 (1.04-3.18) for sequential NETA and for continuous NETA to 3.83 (2.34-5.91) 
after 10 years of use, but the difference was not statistically significant.  
The use of EPT was accompanied with rises in the incidence of both ductal and lobular cancers, yet 
the risk for lobular cancer was already elevated within the first 3 years of use ( SIR 1.35; 1.18-
1.53). The risk was significantly higher for lobular than that for ductal cancer after 10 years of use. 
The use of EPT was accompanied with comparable risk rises in both localized cancer and cancer 
spread to regional nodes.  
 
 
Hormone therapy including levonorgestrel releasing intrauterine system and tibolone and the 
risk for breast cancer (study III) 
In the case control study, parity, age at first birth, and place of residence, were significant 
determinants of breast cancer, and the final model was adjusted with these variables. The risk for 
breast cancer was especially low (0.48; 0.36-0.64) for women with 5 children and an age of under 
25 at the first birth as compared with nulliparous women. The risk for breast cancer was elevated in 
Tampere and Helsinki hospital areas (1.16; 1.07-1.27 and 1.16; 1.08-1.26, respectively), as 
compared to the reference category (Oulu).  
The use of ET, or oral progestagen-only therapy was not associated with an increased risk for breast 
cancer (Table 13), whereas the use of EPT, LNG-IUS alone, or as a complement to estradiol, 
tibolone, and mixed therapy use were accompanied with an elevated risk for breast cancer (Table 
13).  
The continuous use of progestagen as a part of EPT was more strongly associated with an elevated 
risk for breast cancer than sequential use of progestagen, and this risk increased along with an 
increasing duration of exposure. The use of estradiol plus LNG-IUS was accompanied with a more 
than 2–fold elevated risk for breast cancer after 3 years of exposure.   
The use of sequential NETA and MPA with estradiol was accompanied with an increased risk for 
breast cancer, but the risk for breast cancer in users of sequential dydrogesterone with estradiol did 
not reach the significance in any duration category.  
Continuous NETA with estradiol was associated with an increased risk for breast cancer in all 
exposure categories, and the risk increased with an increasing duration of use. Continuous 
estradiol+MPA use was associated with an increased risk for breast cancer after 5 years of use.  
 
 
 
 
 
 
 
 39
Table 13. Relative risk of invasive breast cancer among postmenopausal women using hormone 
therapy (HT)1 
 Cases Controls OR 95% CI p-value 
No user2  5473 17956 1.00 (reference)  
Estradiol-only therapy 991 3300 1.01 0.93–1.09 0.88 
Progestagen-only therapy 138 476 0.97 0.80–1.17 0.73 
LNG-IUS3 329 708 1.53 1.33–1.75 0.001 
Estradiol-progestagen 
therapy 
1731 4243 1.36 1.27–1.46 0.001 
Estradiol plus LNG-IUS 287 473 2.07 1.78–2.41 0.001 
Mixed therapy4 927 2534 1.22 1.12–1.33 0.001 
Tibolone5 80 178 1.36 1.15–1.96 0.003 
1Adjusted with age, parity, age at first birth and health care district. OR = odds ratio; CI = confidence 
interval.  
2Had bought HT never or for less than 6 months.  
3Levonorgestrel releasing intrauterine system.  
4Mixture of estradiol-only, progestagen-only, or estradiol-progestagen therapy.  
5At least 6 months tibolone with other type of therapy.  
 
 
Different doses and routes of administration of norethisterone acetate as a part of hormone 
therapy and the risk for breast cancer (study IV) 
In this study, 885 cases altogether were NETA users, of which 329 had used oral sequential 
NETA+estradiol. The majority (85 %) of 329 cases had taken a ”high” NETA dose (1mg) 
sequentially as a complement to 2.0 mg of estradiol, and only 15% had used 1mg of estradiol, and 
therefore this group was analysed on its own regardless of the dose of estradiol. In the sequential 
“high” dose NETA+estradiol -group, the risk was elevated after 3 years, and increased with 
increasing duration of exposure being 1.89 (1.43-2.50) after 5 years of exposure. The continuous 
NETA+estradiol was divided into two categories; to “high” dose (1mg NETA+2mg estradiol) and  
“low” dose (0.5 mg NETA+1mg estradiol). The use of “low” dose NETA+estradiol was associated 
with an increased risk for breast cancer in less than 3 years of use (1.94; 1.39-2.70), but the use of 
“high” dose was not. After 3 years of use, no statistical difference between “low” and “high” dose 
NETA+estradiol was seen (Table 14).  
Both sequential and continuous transdermal NETA, together with estradiol, were accompanied with 
an elevated risk for breast cancer in less than 3 years of exposure. In less than 5 years of exposure, 
the association was stronger for the continuous use of NETA. Transdermal sequential and the  
continuous administration of NETA was comparable to the oral one in the risk for breast cancer. 
In the group of mixed NETA use, the duration of the exposure was a significant determinant for the 
risk of breast cancer. The mixed NETA group was comparable to sequential NETA+estradiol  with  
regard to breast cancer risk. 
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Table 14. Risk for breast cancer among postmenopausal women using oral sequential or continuous 
norethisterone acetate+estradiol by dose and duration 
Sequential NETA1 (1mg NETA 
for 10-14 days/month+estradiol) 
case control OR2 95% CI p-value 
< 3 years 164 441 1.21 1.01–1.46 0.04 
3 < 5 yrs 87 199 1.48 1.14–1.90 0.003 
≥ 5 yrs 78 146 1.89 1.43–2.50 0.001 
“Low” dose continuous NETA 
(NETA 0.5 mg+estradiol 1 mg) 
     
< 3 years 57 98 1.94 1.39–2.70 0.001 
3 < 5 yrs 27 39 2.45 1.49–4.02 0.001 
≥ 5 yrs 6 7 3.08 1.02–9.23 0.05 
”High” dose continuous NETA 
(NETA 1 mg+estradiol 2 mg)  
     
< 3 years 48 131 1.21 0.87–1.70 0.26 
3 < 5 yrs 38 74 1.71 1.15–2.54 0.007 
≥ 5 yrs 37 64 2.03 1.34–3.06 0.001 
1Norethisterone acetate. 
 2Adjusted with age, parity, age at first birth and health care district, no user as reference category. 
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DISCUSSION 
 
Breast cancer is a major concern among women who consider starting the use of HT or who are 
already using HT. Due to  national differences in the use of HT (Chlebowski et al 2003, Stahlberg et 
al 2004, Fournier et al 2008), mammography screening programs, genetic background and life-
style habits, the associations between HT use and breast cancer should be studied in each country 
where HT is being used. We conducted four studies to compare different hormone therapies as 
regards risks for breast cancer in Finland. The focus was on estrogen-only therapy first, because 
estrogen is the only hormone which alleviates menopausal symptoms. Furthermore, hysterectomy 
rates have been high in Finland; approximately 20% of women (Vuorma et al 1998) underwent a  
hysterectomy by age of 60 prior to our study period, and, unopposed estrogens are allowed only for 
hysterectomized women. In Finland, estradiol and estriol-based  regimens are used, in contrast to 
several previous studies where CEE have been mostly used (Li et al 2000, Newcomb et al 2002, 
Daling et al 2002, Daling et al 2003, Li et al 2003a, Anderson et al 2004).  
One important source of error in epidemiological studies on the risk of breast cancer in HT users is 
inaccurate documentation on the use of HT (Collaborative Group on Hormonal Factors in Breast 
Cancer 1997, Li et al 2000, Bush et al 2001, Beral et al 2003, Newcomb et al 2002, Stahlberg et al 
2004). Recall bias is probably present in all studies based on interviews; women diagnosed with 
breast cancer are more likely to recall the use of HT than women without breast cancer. We 
retrieved the use of HT from the medical reimbursement register of the National Social Insurance 
Institution, which includes all the details of HT purchases since 1994. Thus, we could accurately 
assess the type, dose and duration of HT for the entire follow-up period, but some women certainly 
have used HT before the register was operational. Because HT is only partly reimbursed, women 
have to spend their own money for the treatment. Thus, it is very likely that the women truly used 
the HT preparations they had bought. 
In the cohort studies we could not control confounders such as parity, age at the birth of the first 
child, place of residence, socioeconomic status, weight, age at menarche or age at menopause. 
However, socioeconomic differences among postmenopausal HT users and nonusers declined in 
Finland by the 1990s (Topo et al 1999). Therefore, it appears unlikely that there would have been 
major differences in the confounders between HT users and the national average in our study. In 
addition, the rate of BRCA1/2 mutations in unselected Finnish breast cancer patients is low (1.8%) 
(Syrjakoski et al 2000); thus, it seems unlikely that these women could have accumulated into our 
cohort. In case-control studies, important confounders such as age at the first birth and parity could 
be controlled, and the health care district was also included as a variable. Because the mean age at 
menopause is 50-52 years (McKinlay et al 1992), we only included women who were at least 50 
years of age to confirm that we studied truly postmenopausal women.  Although some women had 
used HT before the age of 50 years, such a possible use should not modify the risk for breast cancer 
significantly. Moreover, a late age at menopause is associated with an increased risk for breast 
cancer, and these women start the use of HT later (Cuzick 2003). Therefore, both these factors may 
contribute to the speculation that our risk estimates related to the short use of EPT may be slightly 
too high.  
To get prescriptions, the HT users must visit their doctors regularly. At these appointments, breasts 
have most likely been palpated and examined by mammogram, if needed. This may have resulted in 
a breast cancer detection bias in HT users, and this might be supported by a significantly increased 
incidence of carcinoma in situ in our ET cohort. However, since 1987, organized mammogram 
screenings have been offered to all women between 50 and 60 years of age (in some communities 
up to 69 years) in Finland. The coverage of these free-of-charge screenings is 95% among 50-59 
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years old women, and 90% of invited women actually participate the screenings (Sarkeala et al 
2008). This policy should reduce the impact of a possible detection bias in our cohort.  
In the cohort studies, we compared the incidence of breast cancer in ET and EPT users with that in 
the whole age-matched population, including those using any HT.  It is known that up to 40% of 
Finnish women around 55 years of age have used HT (Rutanen and Ylikorkala 2004) but according 
to our data, approximately 10-15% of women use such a therapy for more than 3 years. Such a 
proportion of moderate-risk women in the reference population dilutes the observed relative risk 
estimate only marginally towards unity and should not affect the conclusions (Pukkala et al 1997). 
In our cohort study, the use of estradiol-only therapy for more than 5 years was accompanied with 
an elevated incidence for breast cancer (SIR 1.44; 1.29–1.59). However, the risk for breast cancer 
was not increased among ET users in the case control study. These contradicting results could be 
explained due to the difference in age and exposure duration among users. In the cohort study, all 
women 50 to 85+ years were included with some of those using ET for decades, and the use of ET 
before register opening could have been possible, while in the case-control study, the users were  
aged 50-62, when the exposure was significantly shorter. Our data are in line with other studies 
(Collaborative Group on Hormonal Factors in Breast Cancer 1997, Bush et al 2001, Li et al 2003a, 
Colditz et al 2000, Stahlberg et al 2004, Fournier et al 2008). The use of CEE only was not 
accompanied with an elevated risk for breast cancer in a randomized controlled trial (HR 0.77; CI 
0.59–1.01) (Anderson et al 2004), while in a large cohort study in the UK; the current use of ET 
was associated with an elevated risk of breast cancer for the use of less than 5 years (RR 1.25; 1.10-
1.41) (Beral et al 2003). 
Due to the established adverse effects of HT, including breast cancer (Collaborative Group on 
Hormonal Factors in Breast Cancer 1997, Warren 2004, Anderson et al 2004, Collins et al 2005, 
Conner et al 2008), the recommendations at present are to use HT at the lowest possible doses for 
the shortest possible duration (The International Menopause Society 2007, The North American 
Menopause Society, 2008). However, only a few studies have compared the breast cancer risk 
associated with different doses of estrogen. Some studies suggest that the impact of estrogen on 
breast cancer risk could be dose-dependent (Colditz et al 2000, Porch et al 2002), while a large 
cohort study from the UK did not find any dose-dependence (Beral et al 2003). Although our data 
did not confirm any significant trend between increasing daily dose of estradiol and the risk of 
breast cancer, higher doses of oral estradiol were accompanied with a slightly higher risk of breast 
cancer than the lower doses, the cut-off dose level was ≥1.9 mg/d. The editorial commented, based 
on our data, that perhaps clinicians should prescribe low-dose estrogen-only regimens also to 
nonhysterectomized women and just monitor the endometrium with ultrasound and/or biopsies 
(Collins 2006). Furthermore, we did not find any association between breast cancer and vaginally 
used estrogens or oral estriol. Thus, these regimens can be used without a fear of increased breast 
cancer risk. 
 The use of transdermal HT might have some vascular benefits compared to the oral one 
(Cacciatore et al 2001, Strandberg et al 2003, Scarabin et al 2003, Canonico et al 2008). However, 
we did not find any differences in breast cancer risk between these routes of administrations, and 
the conclusion was the same for ET and EPT.  This is in line with the British (Beral et al 2003) and 
French data (Fournier et al 2005, 2008).These data might imply that different estrogenic and 
progestagenic milieu in users of oral and transdermal ET or EPT might similarly affect  breast cells. 
It is established that the use of combined estrogen-progestagen therapy is associated with a higher 
risk elevation for breast cancer than is the sole use of estrogen (Collins et al 2005). Our data support 
this conclusion. However, an increased risk for breast cancer in our studies was seen already in 3 
years of use, while the majority of the previous studies report that the first 5 years of use does not 
associate with a risk elevation for breast cancer (Collaborative Group on Hormonal Factors in 
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Breast Cancer 1997). Yet, some studies have also  found increased risk for breast cancer already 
within the first 5 years of use (Beral et al 2003, Fournier et al 2008, Flesch-Janys et al 2008). 
The continuous EPT showed higher risks for breast cancer than sequential EPT in both our 
studies on EPT, which is in line with previous data (Collins et al 2005, Flesch-Janys et al 2008), 
although some other studies have reported no difference in this risk between sequential and 
continuous EPT products (Newcomb et al 2002, Beral et al 2003, Li et al 2003a, Opatrny et al 
2008). National differences in the use or content of various EPT preparations may be one 
explanation for this discrepancy. It is noteworthy that in the case control study we could control 
some important confounders, while in the cohort study this was not possible. 
The data are sparse on the possible differences between various progestagens in regard to the 
breast cancer risk. A British study reported comparable risks for users of EPT regimens containing 
MPA, NETA and LNG (Beral et al 2003). In our cohort study, more than 5 years of use of 
NETA+estradiol was accompanied with a higher risk for breast cancer compared to MPA+estradiol; 
similar results were reported during our study from Germany (Flesch-Janys et al 2008). It is 
possible that different progestagens, together with estradiol, affect breast tissue differently 
(Pasqualini et al 1998, Sitruk-Ware 2004). The progestagen load in women using NETA containing 
regimens; e.g. continuous NETA products also release twice as much NETA than a sequential 
regimen, whereas the dose-difference is much smaller between continuous and sequential MPA 
products. In the case control study, we did not find any significant differences between NETA and 
MPA containing EPT regimens. However, these women were between 50–62 years of age and had 
shorter exposure of EPT. Perhaps longer exposures are needed to reveal possible differences 
between various progestagens. The use of EPT containing dydrogesterone was not associated with a 
significantly elevated risk for breast cancer in the cohort or case control study. This is in agreement 
with data from France (Fournier et al 2008). However, a relatively small sample size limits the 
conclusions about the breast safety of dydrogesterone in our study. 
It is known that various progestagens, including NETA, have a dose-dependent response in the  
endometrium (Stanczyk 2003, van de Weijer et al 2007). In theory, this could be applied to breast 
tissue as well. We compared the modern “low” (0.5 mg+1mg) and older “high” (1mg+2mg) doses 
of NETA+oestradiol regimens in regard to the risk for breast cancer. However, no significant 
difference in breast cancer risk emerged between these two regimens. This may indicate that there is 
no dose-dependence between NETA (as a part of EPT) and the risk for breast cancer, at least with 
the doses which are available in Finland.  
One important and unexpected finding in our study was the increased risk for breast cancer 
associated with LNG-IUS use, either alone or in combination with estradiol, among 
postmenopausal women.  It is not likely, that such a low dose of LNG released by the device would 
cause cancerous changes in breast cells (Raudaskoski et al 2002). Yet LNG-IUS is one mode of 
continuous regimen which in general carries a higher risk than a sequential regimen (Collins et al 
2005). Furthermore, the use of continuous LNG+estrogen in both the oral or transdermal modes of 
administration has shown higher risks compared to other progestagens, although the difference has 
not been significant (Beral et al 2003, Flesh-Janys et al 2008). Thus, LNG, being one of the most 
potent progestagens (Stanczyk 2003), could have an impact on the development of breast cancer, 
even in low doses. However, there is a chance of selection bias in our study; women characterized 
with an increased risk for breast cancer could have been fitted with an IUS. These characteristics 
may include hyperestrogenic states, such as obesity, or higher age at spontaneous menopause. Also 
a family risk for breast cancer may have led to the insertion of the LNG-IUS, due to the “low” 
release of LNG. Thus, a truly randomized prospective trial might be needed to assess the impact of 
LNG-IUS+estradiol on the for breast cancer.  
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Only a few studies have analyzed the association between tibolone and breast cancer, some of those 
reporting increased risk (Beral et al 2003, Stahlberg et al 2004, Kenemans et al 2009), and some 
have found no effect (Opartny et al 2008). In our study the use of tibolone was associated with an 
increased risk for breast cancer (2.5mg/d, OR 1.36;1.15–1.96). However, women using tibolone 
might have been characterized with an increased risk for breast cancer, as the users of LNG-IUS, 
and thus the risk could have been modified. The dose-dependence can be important; previous 
studies included the conventional dose of tibolone (2.5mg), while a randomized trial on 
osteoporotic elderly women demonstrated that a smaller dose of tibolone (1.25 mg/day) led to a 
significantly reduced risk for breast cancer (Cummins et al 2008).  
It as been suggested that HT use favours the benign character of breast cancer (Collaborative 
Group on Hormonal Factors in Breast Cancer 1997, Delgado et al 2001, Manjer et al 2001, Cheek 
et al 2002, Daling et al 2002). However, we saw similar risk elevations for localized breast cancer 
and cancer spread to regional lymph nodes, which speaks against the benignity of breast cancer in 
HT users. The use of EPT, and to a lesser extent ET, increases breast density (Greendale et al 1999, 
Lundstrom et al 1999, Bremnes et al 2007), which in turn reduces the diagnostic accuracy of 
mammograms (Kavanagh et al 2000). This might explain, at least in part, the increased incidence of 
cancers spread to regional nodes, both in users of ET and EPT.  
The use of EPT is associated more strongly with a lobular than with a ductal type of breast cancer 
(Collins et al 2005, Reeves et al 2006, Rosenberg et al 2006, Li et al 2008, Flesch-Janys et al 
2008), whereas the impact of ET on the type of breast cancer is less clear (Li et al 2008, Flesch-
Janys et al 2008). Our data show that the use of ET is associated similarly with ductal and lobular 
types of breast cancer in Finland, whereas the use of EPT was associated with a higher risk for 
lobular than that for ductal cancer. It was conspicuous that a risk elevation for lobular cancer was 
already significant within the first 3 years of EPT use. 
Finally, I would like to consider if the use of HT could be a cause or promoting factor for breast 
cancer. Epidemiological data can seldom prove that a certain agent or factor, e.g. HT, could be the 
cause of cancer. Our data show associations between HT and breast cancer, but whether the use of 
HT would cause breast cancer is still an open question. Yet, in view of the effects of estrogens and 
progestagens on the breast cells (Yager and Davidson 2006, Conner 2007), such a possibility exists. 
Furthermore, The International Agency for Research on Cancer has classified EPT as a 
carcinogenic agent (IARC 2007) based on evidence from experimental animals and in exposed 
humans in which EPT acts through a relevant mechanism of carcinogenicity. However, a significant 
increase in the risk for breast cancer within the first 3 years of EPT use may imply that the use of 
EPT does not initiate the cancer, but promotes the growth of a pre-existing cancer (Speroff 2008, 
Horwitz and Sartorius 2008), because in general, it takes approximately 7 years for a malignant cell 
to become detectable by mammography. The increase in the risk for breast cancer rather soon after 
the initiation of HT suggests that HT use may lead to an earlier detection of pre-existing tumours. 
Yet, in practical terms, the use of ET for at least 5 years means 4 extra breast cancer cases per 1000 
women and the use of EPT for 5-10 years means 6 extra cases per 1000 women. 
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CONCLUSIONS 
 
On the basis of the present work, the following conclusions can be drawn: 
1. Oral or transdermal estradiol for less than 5 years is not associated with an increased risk of 
breast cancer, but such a risk appears with the use of > 5 years. Estradiol use is associated 
with comparable risk rises in ductal and lobular types of breast cancer, and breast cancers at 
diagnosis are equally often local or spread to regional lymph nodes. Vaginal estrogens are 
not associated with an increased risk for breast cancer.  
2. The use of EPT is accompanied with an increased risk for breast cancer within the first 3 
years. The risk elevates with the exposure time and is lower for sequential than for 
continuous EPT regimens. Oral and transdermal EPT uses present comparable risk 
elevations for breast cancer. The EPT products releasing NETA are accompanied with 
higher elevations after 5 years of use in the risk for breast cancer than for products releasing 
MPA or dydrogesterone. The use of EPT is associated with risk rises in ductal and lobular 
cancers, and the risk for lobular cancer is already elevated within the first 3 years of use. 
The risk is significantly higher for lobular than that for ductal cancer after 10 years of use. 
The use of EPT is accompanied with comparable risk rises in both localized cancer and 
cancer spread to regional nodes.  
3. Estradiol alone in the case control study did not associate with a risk for breast cancer. The 
difference between cohort and case control data in ET may derive from age differences in 
users. Progestagen alone does not relate to a rise in the risk for breast cancer in recently 
postmenopausal women. The use of EPT is associated with an elevated risk for breast cancer 
in less than 5 years of use, and the risk elevation is higher for continuous EPT rather than for 
sequential EPT use. The use of tibolone, a LNG-IUS or as a complement to estradiol, is 
accompanied with an elevated risk for breast cancer. 
4. The dose of NETA (“low” or “high” dose) as a part of EPT is not a determinant of breast 
cancer.  NETA together with estrogen given orally or transdermally, is accompanied with 
comparable risk elevations for breast cancer. A continuous mode of administration presents 
a stronger association with breast cancer. Thus, these data do not support a clear dose-
dependence between daily doses of NETA and breast cancer risk. 
5. Taken as a whole, the use of HT for 5-10 years is associated with 4-6 extra cases of breast 
cancer among 1000 Finnish HT users; this risk evaluation depends on the mode of HT. This 
unavoidable risk must be accepted by each user, and it must be considered in balance with 
the undisputable health benefits which also are associated with the use of HT. Each HT user 
should be thoroughly informed of the risks and benefits, so that she herself can make a 
knowledge-based decision to use or not to use HT. 
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